Amelioration effects of the soybean lecithin-gallic acid complex on iron-overload-induced oxidative stress and liver damage in C57BL/6J mice

Pharm Biol. 2023 Dec;61(1):37-49. doi: 10.1080/13880209.2022.2151632.

Abstract

Context: Gallic acid (GA) and lecithin showed important roles in antioxidant and drug delivery, respectively. A complex synthesized from GA and soybean lecithin (SL-GAC), significantly improved bioavailability of GA and pharmacological activities. However, the antioxidant activity of SL-GAC and its effect on iron-overload-induced liver injury remains unexplored.

Objective: This study investigates the antioxidant properties of SL-GAC in vitro and in mice, and its remediating effects against liver injury by iron-overloaded.

Materials and methods: In vitro, free radical scavenging activity, lipid peroxidation inhibition, and ferric reducing power of SL-GAC were measured by absorbance photometry. In vivo, C57BL/6J mice were randomized into 4 groups: control, iron-overloaded, iron-overloaded + deferoxamine, and iron-overloaded + SL-GAC. Treatments with deferoxamine (150 mg/kg/intraperitioneally) and SL-GAC (200 mg/kg/orally) were given to the desired groups for 12 weeks, daily. Iron levels, oxidative stress, and biochemical parameters were determined by histopathological examination and molecular biological techniques.

Results: In vitro, SL-GAC showed DPPH and ABTS free radicals scavenging activity with IC50 values equal to 24.92 and 128.36 μg/mL, respectively. In C57BL/6J mice, SL-GAC significantly reduced the levels of serum iron (22.82%), liver iron (50.29%), aspartate transaminase (25.97%), alanine transaminase (38.07%), gamma glutamyl transferase (42.11%), malondialdehyde (19.82%), total cholesterol (45.96%), triglyceride (34.90%), ferritin light chain (18.51%) and transferrin receptor (27.39%), while up-regulated the levels of superoxide dismutase (24.69%), and glutathione (11.91%).

Conclusions: These findings encourage the use of SL-GAC to treat liver injury induced by iron-overloaded. Further in vivo and in vitro studies are needed to validate its potential in clinical medicine.

Keywords: Phenolic acid; antioxidant activity; excessive iron; hepatic damage.

MeSH terms

  • Animals
  • Antioxidants / therapeutic use
  • Deferoxamine / metabolism
  • Deferoxamine / pharmacology
  • Deferoxamine / therapeutic use
  • Gallic Acid / pharmacology
  • Glycine max
  • Iron / metabolism
  • Iron Overload* / drug therapy
  • Iron Overload* / metabolism
  • Iron Overload* / pathology
  • Lecithins / metabolism
  • Lecithins / pharmacology
  • Lecithins / therapeutic use
  • Lipid Peroxidation
  • Liver
  • Liver Diseases* / drug therapy
  • Mice
  • Mice, Inbred C57BL
  • Oxidative Stress

Substances

  • Lecithins
  • Antioxidants
  • Gallic Acid
  • Deferoxamine
  • Iron

Grants and funding

This study was supported by Project of Jilin Province Medical and Health Talents Special [JLSWSRCZX2021-036].